Search

Displaying results 4121 - 4130 of 5263 in total
  1. Drug

    Apramycin

    go.drugbank.com/drugs/DB04626
    InvestigationalVet approved

    Apramycin is an aminoglycoside antibiotic and has a bactericidal action against many gram-negative bacteria. Apramycin is a structurally unique antibiotic that contains a bicyclic sugar moiety and a monosubstituted deoxystreptamine. It i...

  2. Drug

    XL844

    go.drugbank.com/drugs/DB05149
    Investigational

    XL844 is investigated for the use and treatment solid tumors. XL844 is a solid. XL844 is a potent inhibitor of the checkpoint kinases CHK1 and CHK2, which induce cell cycle arrest in response to a variety of DNA damaging agents. Known dr...

  3. Drug

    Opaganib

    go.drugbank.com/drugs/DB12764
    Investigational

    Opaganib, also known as ABC294640, is a selective sphingosine kinase-2 (SK2) (https://go.drugbank.com/polypeptides/Q9NRA0) inhibitor that is orally administered. This drug has potential anticancer, anti-inflammatory, and antiviral activi...

  4. Drug

    Carbenicillin

    go.drugbank.com/drugs/DB00578
    Approved

    Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function.

    Synonyms: N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-6-yl)-2-phenylmalonamic acid
  5. Drug

    ANA971

    go.drugbank.com/drugs/DB05127
    Experimental

    ANA971, an orally administered prodrug of isatoribine. Isatoribine is a nucleoside analog in development for the treatment of chronic hepatitis C virus (HCV) infection. ANA971 is a prodrug designed to improve the oral bioavailability of ...

  6. Drug

    DL-alpha tocopheryl acetate

    go.drugbank.com/drugs/DB14477
    Approved

    Mixtures: UltimateCare ONE NF, Vinate AZ
  7. Drug

    CHO Cells Recombinant Vaccine

    go.drugbank.com/drugs/DB15893
    Experimental

    This vaccine candidate, developed in China, uses SARS-CoV-2 protein subunits that are entirely engineered, created, and secreted by Chinese Hamster Ovary (CHO) cells[A219758]. … The vaccine candidate is sponsored by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. and is undergoing phase I clinical trials to evaluate safety and tolerability.

  8. Drug

    IR208

    go.drugbank.com/drugs/DB05106
    Investigational

    IR208 is a synthetic T-Cell receptor peptide vaccine developed by Immune Response Corporation. … It contains three peptides (BV5S2, BV6S5 and BV13S1) expressed by T-Cells in over 90% of MS patients. IR208 is currently undergoing Phase II studies in a 200-patient trial.

  9. Drug

    Pimicotinib

    go.drugbank.com/drugs/DB18972
    Investigational

    It was initially developed by Abbisko Therapeutics Co in collaboration with Merck KGaA. [L53748] Pimicotinib was granted Fast Track Designation in December 2023 by the FDA. [L53753]

    Synonyms: 1-Pyrrolidinecarboxamide, 3,3-dimethyl-N-[6-methyl-5-[[2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl]oxy]-2-pyridinyl]-2-oxo-, 3,3-Dimethyl-N-[6-methyl-5-[[2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl]oxy]-2-pyridinyl]-2-oxo-1-pyrrolidinecarboxamide
  10. Drug

    Agalsidase beta

    go.drugbank.com/drugs/DB00103
    ApprovedInvestigational

    Agalsidase beta is a recombinant human α-galactosidase A similar to agalsidase alfa. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater b...